6 / 27
Addiction Psychiatry 2018
Journal of Addiction Research & Therapy
ISSN: 2155-6105
Page 20
August 13-14, 2018
Madrid, Spain
8
th
International Conference on
Addiction Psychiatry
Background & Objectives:
Opioid use disorders are common,
chronic relapsing disorders. Buprenorphine (BUP) is an FDA
approved medication in the treatment of opioid use disorders,
but patient adherence to this medication remains a challenge.
To identify risk factors for non-adherence, this chart review
study examined the association between DSM-IV Axis I
psychiatric disorders, substance use, demographics, and
adherence to BUP-naloxone in African–American patients.
Methods:
Charts were selected of patients who had 5 visits and
completed psychometric screens (patient health questionnaire,
mood disorder questionnaire, and a posttraumatic stress
disorder questionnaire) at the time of the initial visit (N ¼
50). Urine drug screens (UDS) were also obtained. Treatment
adherence was defined as BUP presence in UDS for 80% of the
visits.
Results:
A total of 48% of patients were adherent to treatment.
Non-adherent patients had higher rates of use for not only
opioids, but also cocaine, and alcohol. Cocaine use was
associated with BUP-naloxone non-adherence even after
controlling for opioid use. Attendance in cognitive behavioral
group therapy sessions (CBT) was significantly associated
with adherence. Patients endorsing PTSD symptoms showed
higher adherence to treatment compared to those who did not
endorse these symptoms.
Conclusions & Scientific Significance:
Our results indicate
that alcohol and illicit substance use is associated with non-
adherence to BUP-naloxone treatment, and suggests that CBT
and efforts to promote abstinence from non-opioid substance
use may improve adherence among African–Americans. These
findings contribute to growing literature on understanding
adherence to BUP-naloxone, which is critical to reduce
morbidity and mortality.
Biography
Dr. Kumari received MD Degree from Dow Medical College Karachi, Paki-
stan. In addition, in 2004 she received a Master’s Degree in Public Health
(MPH) from George Washington University, Washington DC.
Dr. Kumari has a broad solid background in clinical psychiatry research, with
specific training and expertise in managing, coordinating, and collaborat-
ing on multiple clinical research projects. As a project manager Dr. Kumari
gained substantial research experience on NIDA funded research project-
Seek Treat, Reach, and Identify pretrial Defendants Enhancement (STRIDE)
in collaboration with the Yale School of Medicine, George Mason University
and Howard University Hospital. The project STRIDE is a placebo-controlled,
randomized controlled trial of buprenorphine treatment for HIV-infected,-in-
fected, opioid dependent, community-supervised defendants or offenders.
vsuneeta@yahoo.comFactors associated with non-adherence to buprenorphine-
naloxone among opioid dependent African–Americans: a
retrospective chart review
Suneeta Kumari
1
, Partam Manalai
1
, Sharlene Leong
1
, Alese Wooditch
2
,
William B Lawson
3
and
Malik Mansoor
1
1
Howard University, USA
2
George Mason University, USA
3
The University of Texas at Austin, USA
Suneeta Kumari et al., J Addict Res Ther 2018, Volume 9
DOI: 10.4172/2155-6105-C2-039